In recent years, therapeutics that block inhibitory checkpoints or activate stimulatory checkpoints have proven effective in restoring anti-tumor immune responses and treating cancer. FDA-approved drugs targeting immune checkpoints such as cytotoxic T-lymphocyte antigen (CTLA-4), programmed cell death (PD-1), and its ligand (PD-L1) have revolutionized oncology by providing new avenues for treating various types of cancers.
With immune checkpoint inhibitors being widely used as novel immunotherapy agents, immune checkpoint assays are critical for understanding the mechanisms of immune checkpoint blockade therapy and accelerating cancer immunotherapy development.
The following immune checkpoint assays can fulfill a variety of research needs:
Immune Checkpoint Binding and Interaction Assays: These assays provide initial characterization of immune checkpoint inhibitor candidates.
Immune Checkpoint Functional Assays: Functional assays, such as the T cell proliferation assay, cytokine production assay, and T cell cytotoxicity assay, test the immuno-modulatory activities of checkpoint inhibitors.
Immune Checkpoint Potency and Stability Assays: Potency and stability testing are required to ensure the reliability, effectiveness, and safety of biopharmaceutical products.
The immune checkpoint proteins have received increasing attention due to their essential role in the immune system. To create more potent cancer treatments, biotin labeling and immune checkpoint cell line development services are crucial for researchers. These services facilitate the study of immune checkpoint therapy and simplify assay development.
Many international CRO companies, including Creative Biolabs, offer a variety of biotin-labeled immune checkpoint products to support immune checkpoint research. Creative Biolabs has optimized technical pipelines for custom immune checkpoint protein labeling, providing a comprehensive set of services, such as immune checkpoint protein biotin labeling and fluorescence labeling.
Furthermore, immune checkpoint stable cell lines are invaluable for researching anti-tumor immunity. These cell lines can be used in manufacturing checkpoint antibodies, drug screening, and pharmacological and toxicological studies. Researchers seeking support from CRO companies should consider the development technologies these companies use, as cutting-edge technologies directly impact the performance and quality of stable cell line products for developing immune checkpoint drugs.
Creative Biolabs, a global biotechnology company with years of experience assisting in the development of immune checkpoint inhibitors, boasts mature and advanced technologies for assays and cell line development. They are dedicated to providing a comprehensive set of immune checkpoint-based therapy development services to accelerate the advancement of innovative immune therapeutics. By leveraging their expertise and state-of-the-art technologies, Creative Biolabs continues to support researchers in making significant strides in cancer immunotherapy.
